ArticleScientific reports2026
p-STAT3 expression associates with prognosis and inflammatory indexes in gastric cancer patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Despite advances in early detection and treatment, the prognosis for advanced gastric cancer (GC) remains poor, highlighting the need to explore molecular mechanisms driving tumor progression. Phosphorylated Signal Transducer and Activator of Transcription 3 (p-STAT3) is a central mediator in these processes, but its role in GC biology and prognostic significance remains controversial. We analyzed p-STAT3 expression in tumor and adjacent normal tissues from 68 GC patients using immunohistochemistry and evaluated associations with inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), tumor characteristics, and survival outcomes. p-STAT3 positivity was significantly higher in GC tissues (32.4%) than in normal tissues (13.2%, p = 0.008). Positive p-STAT3 expression correlated with elevated NLR (p = 0.014) and PLR (p = 0.041). Although tumor stage, size, and lymph node metastasis did not show significant differences in p-STAT3 expression (p > 0.05), multivariate analysis identified p-STAT3 as an independent predictor of poor survival (HR = 5.711, 95% CI 1.180-27.643; p = 0.030). p-STAT3-positive patients had significantly worse cumulative survival rates (47.4%) compared to p-STAT3-negative patients (92.7%, p = 0.001). These results indicate that p-STAT3 overexpression is linked to systemic inflammation and poor prognosis, highlighting its potential as a therapeutic target in GC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.